Cold-chain provider Shanghai Shengsheng joins pharma IPO hopefuls
China’s biggest supplier of temperature-controlled services for the drug sector has renewed a Hong Kong listing plan, raising questions with hefty pre-IPO payouts Key Takeaways: Turnover has grown steadily, driven…
Fading interest in animal health takes bite out of Sinder
The company’s valuation plunged 40% in its latest funding round from four years earlier, as it seeks a Hong Kong listing Key Takeaways: Sinder Technology’s profit declined in 2024, but…
BRIEF: Gavi seeks to claw back $224 million prepayment from Clover
Biotechnology firm Clover Biopharmaceuticals Ltd. (2197.HK) said on Monday that it received an arbitration claim on June 6 seeking return of a $224 million prepayment from global vaccine alliance Gavi.…
Everest Medicines drives growth with AI-powered mRNA pipeline
The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine’s EVM14 cancer vaccine…
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
The veterinary vaccine producer raised a modest $6.9 million in its New York listing by selling just 3% of its shares, as it diversifies into the household pets market Key…
CHINA BULLETIN: TikTok Goes to Washington
In this week’s issue TikTok testifies in Washington, China discovers mRNA vaccines, and also re-discovers Australian coal. On a scale of 1 to 10, we give the week a 4.5 for offshore-listed China stocks.
Fosun Pharma Sells Down BioNTech Stake, Though Divorce Looks Unlikely
The Chinese company profited handsomely from its investment in the German vaccine maker, and is most likely selling the stake to help service its parent’s large debtKey Takeaways:Fosun Pharma said…
Recent Articles
RELATED ARTICLES
-
Can New Hope Dairy out-milk Mengniu and catch up with Yili?
002946.SHE - Jacobio Pharma poised to turn a profit from precision cancer drugs
-
Kinwong runs hot on AI boom, cold on plunging margins
603228.SHG
- Unsated by Hong Kong listing, Knowledge Atlas seeks more funds in Shanghai
- Beneath the radar: How Chinese solar makers and IPO hopefuls are surviving the turbulent U.S. market
- Insilico revenue soars above $100 million on AI drug partnerships
